CLDN6 and neoplasm: Cohorts treated with MVvac2-CLDN6 or MVvac2-gag-CLDN6 experienced an even stronger delay in tumor growth (Fig. 7c) and a further increase of median survival (11 vs. 9 days post initiation of treatment).